Posts Tagged ‘pancreatic cancer’
Andarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study
Tozaride Demonstrates Significant Tumor Reduction in Clinical Study SOMERVILLE, Mass.—May 2, 2017— Andarix Pharmaceuticals, a clinical stage company, announced today the results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using…
Read MoreAndarix and Tulane University Collaborate to Further Research on Mediators of Cancer Cell Signaling
Andarix’ R&D expands to include Notch Influencing Molecules ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for cancers announced today that the Company has entered into an agreement with Tulane University, an institution at the forefront of modern medical innovation, to license the technology and intellectual property concerning Notch Influencing Molecules. The…
Read MoreAndarix Selected to Present at Prominent Drug Development Conferences
ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at two upcoming conferences in Boston, MA this fall. Both conferences are invitation only for presenting companies, and showcase leading drug development organizations working to advance groundbreaking…
Read MoreAndarix Selected to Present at Orphan Drug Congress
ANDARIX Pharmaceuticals, a clinical stage company developing a targeted peptide therapy for small cell lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at the World Orphan Drug Conference in Washington, DC on April 23, 2015. Conference location and agenda information are available at the World Orphan Drug Congress. Andarix’…
Read MoreAndarix Pharmaceuticals’ Targeted Therapy Demonstrates Efficacy in Pancreatic Cancer
Tozaride Demonstrates Pancreatic Tumor Reduction in Animal Model ANDARIX Pharmaceuticals, a clinical stage company, announced today the publication of research findings that demonstrate the ability of its Tozaride targeted peptide therapy to reduce the size of pancreatic cancer tumors. The research paper titled “The Somatostatin Analog Rhenium Re-188-P2045 Inhibits the Growth of AR42J Pancreatic Tumor-Xenografts”…
Read MoreAndarix Pharmaceuticals Selected to Present at International Drug Conference in Copenhagen
ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for small cell lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at the Orphan Drugs Summit to be held in Copenhagen, Denmark from September 17-19, 2014. Conference agenda information are available at www.orphandrugssummit.com. Mr. Adams will highlight recent results…
Read MoreAndarix Pharmaceuticals Receives Pancreatic Cancer Orphan Drug Designation from the FDA
Targeted therapy for pancreatic cancer is based on personalized medicine approach ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung cancer announced today that Tozaride, the Company’s lead candidate for targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the…
Read More